Cargando…
An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies
In patients with hematologic malignancies due to immune system disorders, especially persistent febrile neutropenia, invasive fungal infections (IFI) occur with high mortality. Aspergillosis, candidiasis, fusariosis, mucormycosis, cryptococcosis and trichosporonosis are the most important infections...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369308/ https://www.ncbi.nlm.nih.gov/pubmed/32765009 http://dx.doi.org/10.2147/IDR.S254478 |
_version_ | 1783560754173050880 |
---|---|
author | Shariati, Aref Moradabadi, Alireza Chegini, Zahra Khoshbayan, Amin Didehdar, Mojtaba |
author_facet | Shariati, Aref Moradabadi, Alireza Chegini, Zahra Khoshbayan, Amin Didehdar, Mojtaba |
author_sort | Shariati, Aref |
collection | PubMed |
description | In patients with hematologic malignancies due to immune system disorders, especially persistent febrile neutropenia, invasive fungal infections (IFI) occur with high mortality. Aspergillosis, candidiasis, fusariosis, mucormycosis, cryptococcosis and trichosporonosis are the most important infections reported in patients with hematologic malignancies that undergo hematopoietic stem cell transplantation. These infections are caused by opportunistic fungal pathogens that do not cause severe issues in healthy individuals, but in patients with hematologic malignancies lead to disseminated infection with different clinical manifestations. Prophylaxis and creating a safe environment with proper filters and air pressure for patients to avoid contact with the pathogens in the surrounding environment can prevent IFI. Furthermore, due to the absence of specific symptoms in IFI, rapid and accurate diagnosis reduces the mortality rate of these infections and using molecular techniques along with standard mycological methods will improve the diagnosis of disseminated fungal infection in patients with hematologic disorders. Amphotericin B products, extended-spectrum azoles, and echinocandins are the essential drugs to control invasive fungal infections in patients with hematologic malignancies, and according to various conditions of patients, different results of treatment with these drugs have been reported in different studies. On the other hand, drug resistance in recent years has led to therapeutic failures and deaths in patients with blood malignancies, which indicates the need for antifungal susceptibility tests to use appropriate therapies. Life-threatening fungal infections have become more prevalent in patients with hematologic malignancies in recent years due to the emergence of new risk factors, new species, and increased drug resistance. Therefore, in this review, we discuss the different dimensions of the most critical invasive fungal infections in patients with hematologic malignancies and present a list of these infections with different clinical manifestations, treatment, and outcomes. |
format | Online Article Text |
id | pubmed-7369308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-73693082020-08-05 An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies Shariati, Aref Moradabadi, Alireza Chegini, Zahra Khoshbayan, Amin Didehdar, Mojtaba Infect Drug Resist Review In patients with hematologic malignancies due to immune system disorders, especially persistent febrile neutropenia, invasive fungal infections (IFI) occur with high mortality. Aspergillosis, candidiasis, fusariosis, mucormycosis, cryptococcosis and trichosporonosis are the most important infections reported in patients with hematologic malignancies that undergo hematopoietic stem cell transplantation. These infections are caused by opportunistic fungal pathogens that do not cause severe issues in healthy individuals, but in patients with hematologic malignancies lead to disseminated infection with different clinical manifestations. Prophylaxis and creating a safe environment with proper filters and air pressure for patients to avoid contact with the pathogens in the surrounding environment can prevent IFI. Furthermore, due to the absence of specific symptoms in IFI, rapid and accurate diagnosis reduces the mortality rate of these infections and using molecular techniques along with standard mycological methods will improve the diagnosis of disseminated fungal infection in patients with hematologic disorders. Amphotericin B products, extended-spectrum azoles, and echinocandins are the essential drugs to control invasive fungal infections in patients with hematologic malignancies, and according to various conditions of patients, different results of treatment with these drugs have been reported in different studies. On the other hand, drug resistance in recent years has led to therapeutic failures and deaths in patients with blood malignancies, which indicates the need for antifungal susceptibility tests to use appropriate therapies. Life-threatening fungal infections have become more prevalent in patients with hematologic malignancies in recent years due to the emergence of new risk factors, new species, and increased drug resistance. Therefore, in this review, we discuss the different dimensions of the most critical invasive fungal infections in patients with hematologic malignancies and present a list of these infections with different clinical manifestations, treatment, and outcomes. Dove 2020-07-14 /pmc/articles/PMC7369308/ /pubmed/32765009 http://dx.doi.org/10.2147/IDR.S254478 Text en © 2020 Shariati et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Shariati, Aref Moradabadi, Alireza Chegini, Zahra Khoshbayan, Amin Didehdar, Mojtaba An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies |
title | An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies |
title_full | An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies |
title_fullStr | An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies |
title_full_unstemmed | An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies |
title_short | An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies |
title_sort | overview of the management of the most important invasive fungal infections in patients with blood malignancies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369308/ https://www.ncbi.nlm.nih.gov/pubmed/32765009 http://dx.doi.org/10.2147/IDR.S254478 |
work_keys_str_mv | AT shariatiaref anoverviewofthemanagementofthemostimportantinvasivefungalinfectionsinpatientswithbloodmalignancies AT moradabadialireza anoverviewofthemanagementofthemostimportantinvasivefungalinfectionsinpatientswithbloodmalignancies AT cheginizahra anoverviewofthemanagementofthemostimportantinvasivefungalinfectionsinpatientswithbloodmalignancies AT khoshbayanamin anoverviewofthemanagementofthemostimportantinvasivefungalinfectionsinpatientswithbloodmalignancies AT didehdarmojtaba anoverviewofthemanagementofthemostimportantinvasivefungalinfectionsinpatientswithbloodmalignancies AT shariatiaref overviewofthemanagementofthemostimportantinvasivefungalinfectionsinpatientswithbloodmalignancies AT moradabadialireza overviewofthemanagementofthemostimportantinvasivefungalinfectionsinpatientswithbloodmalignancies AT cheginizahra overviewofthemanagementofthemostimportantinvasivefungalinfectionsinpatientswithbloodmalignancies AT khoshbayanamin overviewofthemanagementofthemostimportantinvasivefungalinfectionsinpatientswithbloodmalignancies AT didehdarmojtaba overviewofthemanagementofthemostimportantinvasivefungalinfectionsinpatientswithbloodmalignancies |